Trial Profile
A multicenter, randomized, double-blind comparison of 4 dose regimens of Pla-695 [giripladib], naproxen, and placebo administered daily for 6 weeks in subjects with active osteoarthritis of the knee
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 02 Jun 2011
Price :
$35
*
At a glance
- Drugs Giripladib (Primary) ; Naproxen (Primary)
- Indications Musculoskeletal pain; Osteoarthritis
- Focus Therapeutic Use
- Sponsors Wyeth
- 27 Dec 2007 Status changed from recruiting to discontinued.
- 25 Nov 2006 New trial record.